As we know, assessment of gene mutations in AML contributes to identifying subgroups with markedly superior outcome (e.g, mutant N PM1 [39] or C/EBPA [40]) and inferior outcome (e.g, mutant C-KIT [41], DNMT3A [27], FLT3 ITD [42], MLL/KMT2A [27] or WT1 [43]). Here, CEBPA is linked to acute myeloid leukemia.